Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166695 | 0.83 | LOX (0.34) | USP14LOXLOXL2RXRAGRIN1 | |
| SCHEMBL30542327 | 0.82 | LOXL2 (0.47) | KCNQ2USP14AAK1LOXL2 | |
| SCHEMBL331281 | 0.82 | NOS3 (0.51) | DYRK1AAAK1LOXLOXL2NOS3 | |
| SCHEMBL31139328 | 0.82 | BACE1 (0.34) | USP14IRAK4LOXLOXL2 | |
| SCHEMBL29411261 | 0.82 | RECQL (0.47) | GRM5USP14HDAC4HDAC1HDAC6 | |
| SCHEMBL1766223 | 0.82 | RECQL (0.47) | GRM5USP14HDAC4HDAC1HDAC6 | |
| SCHEMBL2889185 | 0.82 | LOXL2 (0.47) | KCNQ2USP14AAK1LOXL2 | |
| SCHEMBL25220483 | 0.81 | LOXL2 (0.39) | USP14IRAK4LOXLOXL2NOS3 | |
| SCHEMBL30464975 | 0.81 | RECQL (0.35) | USP14IRAK4 | |
| SCHEMBL21068406 | 0.81 | RECQL (0.35) | USP14IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-03 | — | — | US | disclosed |
| EP-2480547-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | Panmira Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| WO-2011038086-A2 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2044037-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005721-A1 | INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | GRM5 122/4885UHRF1 3079/4885KCNQ2 3246/4885 |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | GRM5 3810/4885UHRF1 3525/4885KCNQ2 4209/4885 |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLRMT, POLR2H | GRM5 3760/4885UHRF1 3472/4885KCNQ2 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.